CureVac N.V. (ETR:5CV)
4.702
-0.048 (-1.01%)
Jun 17, 2025, 9:44 AM CET
CureVac Revenue
CureVac had revenue of 893.00K EUR in the quarter ending March 31, 2025, a decrease of -92.78%. This brings the company's revenue in the last twelve months to 523.70M, up 787.60% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
523.70M
Revenue Growth
+787.60%
P/S Ratio
2.05
Revenue / Employee
579.31K
Employees
983
Market Cap
1.07B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
CureVac News
- 3 days ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders - GlobeNewsWire
- 3 days ago - This Sherwin-Williams Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
- 4 days ago - BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer - Seeking Alpha
- 4 days ago - Stocks making the biggest midday moves: Oracle, Boeing, CureVac, Datadog and more - CNBC
- 4 days ago - Top Stock Movers Now: Oracle, Boeing, CureVac, and More - Investopedia
- 4 days ago - BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
- 4 days ago - BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal - Benzinga
- 4 days ago - CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday - Benzinga